Sign In
Buy GERN
$1.16
-0.0100 (-0.85%)
At Close: Jun 03, 2026
Geron to Participate in the 25th Annual Needham Virtual Healthcare Conference
08:00am, Monday, 06'th Apr 2026
FOSTER CITY, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, to
Geron (NASDAQ:GERN) Share Price Passes Above 200 Day Moving Average – What’s Next?
02:10am, Tuesday, 31'st Mar 2026
Geron Corporation (NASDAQ: GERN - Get Free Report)'s share price passed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $1.38 and traded as high as
Geron Announces Appointment of New Members to its Board of Directors
08:00am, Thursday, 26'th Mar 2026
Patricia S. Andrews and Constantine Chinoporos are proven industry veterans with decades of experience leading and advising biopharmaceutical companies Patricia S. Andrews and Constantine Chinoporos a
Geron Corporation (NASDAQ:GERN) Given Average Recommendation of “Hold” by Analysts
02:30am, Sunday, 22'nd Mar 2026
Shares of Geron Corporation (NASDAQ: GERN - Get Free Report) have been assigned an average rating of "Hold" from the seven analysts that are presently covering the stock, Marketbeat reports. Two analy
Geron: Minimal Sales Growth But A Potential Run-Up Ahead
11:04am, Thursday, 19'th Mar 2026
Geron Corporation's Q4 '25 net product revenues of $48M are similar to those seen in Q4 '24 ($47.5M). Despite fairly flat quarterly revenues, GERN maintains 2026 net product revenue guidance of $220M-
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Wednesday, 18'th Mar 2026
FOSTER CITY, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective March 17, 2026, it granted stock
Almitas Capital LLC Buys Shares of 946,323 Geron Corporation $GERN
03:31am, Sunday, 15'th Mar 2026
Almitas Capital LLC bought a new position in Geron Corporation (NASDAQ: GERN) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The ins
Geron Corporation (GERN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
05:20pm, Tuesday, 10'th Mar 2026
Geron Corporation (GERN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Geron: Why I'm Doubling Down On My 'Sell' Rating After Q4 Earnings
02:08pm, Thursday, 26'th Feb 2026
Current revenue trends of Geron suggest RYTELO is primarily finding its niche in the later-line "salvage" setting, which may continue to moderate near-term growth expectations. Geron's recent strategi
Geron (GERN) Reports Q4 Loss, Misses Revenue Estimates
01:15pm, Wednesday, 25'th Feb 2026
Geron (GERN) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.04 per share a year ago.
Geron Corporation (GERN) Q4 2025 Earnings Call Transcript
12:17pm, Wednesday, 25'th Feb 2026
Geron Corporation (GERN) Q4 2025 Earnings Call Transcript
Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
07:00am, Wednesday, 25'th Feb 2026
Achieved $48 million and $184 million in RYTELO® (imetelstat) net product revenue in Q4 2025 and full year 2025, respectively Reported total operating expenses of $255 million for full year 2025, wit
Geron Plans to Present at Upcoming Investor Conferences
08:00am, Monday, 23'rd Feb 2026
FOSTER CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, tod
Geron (NASDAQ:GERN) Shares Down 6% – What’s Next?
04:36am, Sunday, 22'nd Feb 2026
Geron Corporation (NASDAQ: GERN - Get Free Report)'s share price dropped 6% on Friday. The stock traded as low as $1.82 and last traded at $1.8050. Approximately 1,252,326 shares traded hands during m
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Wednesday, 18'th Feb 2026
FOSTER CITY, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective February 17, 2026, it granted stoc
